Asia Leaders
Uğur Şahin’s US$11.1 Billion Pumitamig Alliance Now Faces the Phase III Arithmetic
Pumitamig has moved from BioNTech’s US$800 million Biotheus acquisition to an alliance worth up to US$11.1 billion. Uğur Şahin must show that encouraging lung-cancer signals survive global Phase III trials and a crowded competitive field.
